Human PD-1-expressing Raji Cells

Human PD-1-expressing B cells

Raji-hPD-1 cells were developed from the Raji cell line, a human B lymphocyte-derived cell line. Raji cells have been successfully used as target cells in CAR-T toxicity assays as well as human effector studies such as antibody-dependent cellular cytotoxicity (ADCC), either with peripheral blood mononuclear cells, natural killer (NK) cells, or T cell-derived Jurkat reporter cells.

PD-1 (programmed cell death 1; also known as CD279) is a type I transmembrane protein expressed at the cell surface of activated and exhausted conventional T cells. PD-1 is an inhibitory immune checkpoint that prevents T-cell overstimulation and host damage. PD-1 interaction with its ligands PD-L1 and PD-L2 induces inhibition of T-cell receptor signaling [1].

Features of Raji-hPD-1 cells:

• Stable overexpression of the human PD-1 gene
• Characterized by a number of cell-surface expressed markers including the B cell receptor (BCR), CD19, and CD20
• Constitutive expression of various immune checkpoints (ICs) such as CD27, CD70, CD80, PD-L1, and 4-1BBL
• The stability for 20 passages following thawing has been verified

Applications for Raji-hPD-1 cells:

• Target cell line for ADCC assays using InvivoGen's Jurkat-Lucia™ NFAT-CD16 cells
• Target cell line for cell toxicity assays using NK or CAR-T cells
• For use in the development of other functional assays

Validation of Raji-hPD-1 cells:

• Overexpression of PD-1 verified by flow cytometry
• Functionally tested as target cells in ADCC assays using anti-human PD-1 monoclonal Abs and Jurkat-Lucia™ NFAT-CD16 cells
• Guaranteed mycoplasma-free

References:

1. Ribas A. and Wolchock J.D., 2018. Cancer immunotherapy using checkpoint blockade. Science. 359:1350-55.